文献速递药物不良反应与药物警戒抗菌药物管理

头孢哌酮/舒巴坦致溶血性贫血伴血小板增多:病例报告与文献复习

Cefoperazone/sulbactam-induced haemolytic anaemia and thrombocytosis: A case report and literature review.
PubMed 文献 · Br J Clin Pharmacol · 2026-01-20

本文报告一例58岁女性肺炎患者,在接受头孢哌酮/舒巴坦(CPZ/SUL)治疗15天后出现血红蛋白、血细胞比容及红细胞计数进行性下降,并伴血小板计数显著升高。直接抗球蛋白试验显示抗IgG强阳性(+++)、抗C3d阴性,结合临床与实验室资料确诊为溶血性贫血及反应性血小板增多。停用CPZ/SUL并间断输注红细胞7天后血液学指标恢复正常;按Naranjo算法评为「很可能」。

要点

  • CPZ/SUL治疗期间应定期监测全血细胞计数,警惕溶血性贫血与血小板增多。
  • 直接抗球蛋白试验抗IgG强阳性、抗C3d阴性支持免疫性溶血性贫血诊断。
  • 疑似药物性溶血时应及时停用CPZ/SUL,必要时给予红细胞输注支持。

核心结论

  • CPZ/SUL治疗可能与免疫性溶血性贫血及反应性血小板增多同时发生,属罕见可疑关联。
  • 临床医生在CPZ/SUL治疗期间应保持对上述潜在血液学不良反应的警觉,并定期监测全血细胞计数。

研究设计与样本

  • 病例报告及文献复习:一例58岁女性肺炎患者,因颅内血肿行神经内镜下清除术,随后行去骨瓣减压术及清创术。

主要发现

  • CPZ/SUL治疗15天后,系列血液检查显示血红蛋白、血细胞比容及红细胞计数进行性下降,伴血小板计数显著升高。
  • 直接抗球蛋白试验抗IgG强阳性(+++)、抗C3d阴性,结合临床与实验室资料确诊溶血性贫血和反应性血小板增多。
  • 停用CPZ/SUL并间断输注红细胞7天后,患者血液学指标恢复正常并获准出院。
  • 按Naranjo算法,该不良反应归类为「很可能」。

关键数值与推荐

  • 直接抗球蛋白试验:抗IgG(+++)强阳性,抗C3d阴性。
  • CPZ/SUL用药15天后出现血红蛋白、血细胞比容、红细胞计数下降及血小板计数显著升高。
  • 停药并间断红细胞输注7天后血液学指标恢复正常。
  • Naranjo算法评定为「很可能」。

临床怎么用

  • 使用CPZ/SUL期间应定期复查全血细胞计数,关注血红蛋白与血小板变化。
  • 出现不明原因血红蛋白下降或血小板升高时,应考虑药物性免疫性溶血性贫血及反应性血小板增多的可能。
  • 怀疑CPZ/SUL相关溶血性贫血时应及时停药,并根据贫血程度给予红细胞输注等支持治疗。

局限性

  • 本文为单例病例报告,CPZ/SUL与溶血性贫血及血小板增多的关联仅为疑似,不能确立因果关系。
  • Naranjo算法评定为「很可能」,非「肯定」,仍需更多证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cefoperazone/sulbactam (CPZ/SUL) is a broad-spectrum β-lactam/β-lactamase inhibitor combination. Drug-induced immune haemolytic anaemia (DIIHA) is a rare yet serious condition, whereas reactive thrombocytosis typically occurs as a secondary response to inflammatory, infectious or neoplastic processes. We report a case of a 58-year-old woman who presented with haemolytic anaemia and reactive thrombocytosis following administration of CPZ/SUL for pneumonia. The patient underwent neuroendoscopic evacuation of the intracranial haematoma, followed by decompressive craniectomy and debridement. Following 15 days of CPZ/SUL therapy, serial blood tests revealed a progressive decline in haemoglobin (HB), haematocrit (HCT) and red blood cell count, accompanied by a marked elevation in platelet count. Furthermore, the strongly positive anti-IgG (+++) and negative anti-C3d direct antiglobulin test results, together with the clinical and laboratory profile, confirmed the diagnosis of haemolytic anaemia and reactive thrombocytosis. After discontinuing CPZ/SUL and providing intermittent red blood cell transfusions over 7 days, the patient's haematological parameters normalized, which permitted discharge. This case presented a rare occurrence of CPZ/SUL-induced haemolytic anaemia and thrombocytosis, classified as 'probable' according to the Naranjo algorithm. This case describes a rare, suspected association between CPZ/SUL therapy and the concurrent development of immune haemolytic anaemia and reactive thrombocytosis. Clinicians should maintain awareness of these potential adverse haematological reactions during CPZ/SUL treatment and institute regular complete blood count monitoring.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ma Q, Liang Q, Liu S, et al. Cefoperazone/sulbactam-induced haemolytic anaemia and thrombocytosis: A case report and literature review. Br J Clin Pharmacol. 2026. PMID: 41555837. doi:10.1002/bcp.70422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。